ImmunityBio, Inc. (IBRX)
NEUTRALFundamental
46
Kurs
$8.03
Marktkapitalisierung
$8.01B
Teil 1 · Was das Unternehmen wert ist
Übersicht
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$166M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-992M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$-309M
Gesamtes Eigenkapital
$-500M
Gesamtverbindlichkeiten
$1.00B
Current Ratio
5.72
Zinsdeckungsgrad
4.21
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$12.75
Aktueller Kurs
$8.03
Sicherheitsmarge
+37.1%
Innerer-Wert-Spanne
$12.11 - $13.39
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
70.2%
P/B-Verhältnis
-
P/FCF
-
Bruttomarge
99.3%
ROIC
-36.0%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-36.0%
WACC
7.5%
ROIC − WACC
-43.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (9)
- EPS shows upward trend
- Gross Margin 99.3%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 184.3%
- Analyst Consensus 90% Buy
- Net Margin Trend -598.6% vs -648.6%
- Piotroski F-Score 5/9
Nicht bestanden (9)
- Price CAGR 3.14%
- ROIC -36.1%
- Operating Margin -151.9%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -193.3%
- Earnings Surprise avg -19.4%
- Share Dilution 38.6%
Nicht verfügbar (9)
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | 72 |
| Mr. Richard Gerald Adcock | President, CEO & Director | 56 |
| Mr. David C. Sachs | Chief Financial Officer | 47 |
| Ms. Regan J. Lauer | Chief Accounting Officer | 55 |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer | 58 |
| Ms. Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | - |
| Ms. Emily Arison | Senior Vice President of Human Resources | - |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors & Cell Therapy | - |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer | - |
| Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular | 75 |
Prüfungsrisiko
6
Vorstandsrisiko
9
Vergütungsrisiko
9
Aktionärsrechterisiko
6
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for IBRX, sourced from Markets Gazette.
- 2/25/2026POSITIVEImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio Inc. has significantly exceeded analyst expectations, driving a surge in its stock price due to exceptional financial results. Sales of its drug Anktiva demonstrated an impressive 750% increase, contributing to an overall fivefold revenue growth that comfortably beat estimates. This substantial revenue beat, coupled with a new strategic partnership in Saudi Arabia, fuels the company's future growth prospects. Investors should closely monitor the long-term impact of these sales figures and the partnership on ImmunityBio's trajectory within the biopharmaceutical sector.
- 2/23/2026POSITIVEStock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio captured the market's attention on February 23, 2026, with its stock surging on extraordinary news: revenue from its flagship drug, Anktiva, jumped by a staggering 700%. This phenomenal figure overshadowed the company's current, albeit deep, operating losses. Investors are clearly betting on the long-term potential of the drug and the company's ambitious global expansion strategy. While the losses remain a factor to watch, the revenue growth trajectory suggests strong market adoption and a promising future. The market's reaction indicates that top-line growth is currently the most powerful catalyst for the stock's valuation, outweighing concerns about short-term profitability.
via Markets Gazette